Grants & Funding

Large Grant


This funding opportunity supports the development and publication of a clinical or translational project which will immediately impact research projects within CARRA or result in a larger collaborative grant that furthers the CARRA mission. New or early investigators are encouraged to apply and will be afforded special consideration.  A successful application may be for:

  • an all-inclusive clinical or translational research project; or
  • a pilot research project, that if successful, could lead to extramural funding.

Preference will be given to submissions which are collaborative and leverage current CARRA network resources or will further develop the CARRA network.

The application portal is scheduled to open in early September.


IMPORTANT UPDATE FOR GRANT APPLICANTS USING CARRA REGISTRY DATA/SAMPLES

2020 FALL GRANT CYCLE DSSC REQUESTS MUST BE SUBMITTED BY AUGUST 15.

Grant applicants that intend to utilize the CARRA Registry or CARRA-related data and/or samples (including Legacy Registry and APPLE data/samples) must receive approval from the CARRA Data Sample Share Committee (DSSC) prior to submitting their grant applications. These requests take 4-6 weeks to process.

For more information on requesting data/samples and to access the request form, please visit the CARRA Data and Samples Request area of the wiki.

 

Grant applications that propose collection of any new data or biosamples via the CARRA Registry and/or via CARRA sites must include a letter of support (LOS) from CARRA’s Research and Registry Oversight Committee (RROC).

The deadline for 2020 Fall Grant Cycle RROC requests has passed.

 

Applications that do not meet these request deadlines will result in an administrative decline. If you have any questions regarding this requirement, email [email protected].


CARRA-Arthritis Foundation Large Grant Required Submission Materials

  • Letter of Intent (LOI) submitted by September 1
  • Project Summary/Abstract (300 word max)
  • Lay Summary (150 word max)
  • Resubmission Modifications, if applicable (1 page limit) (Download template: WORD)
    • Resubmission modification is required if the applicant has previous submitted a similar project. Applicants should provide an explanation of what has changed from a prior application. Examples would include addressing budget differences or weaknesses the reviewers found in an earlier application.
  • Specific Aims (1 page limit) (Download template: WORD)
  • Research Plan (5 page limit) (Download template: WORD)
  • Project Timeline (3 page limit) (Download template: WORD)
  • References (no page limit) (Download template: WORD)
  • Budget Table (2 page limit) (Download template: WORD)
    • All Primary Investigators (PI) are required to dedicate effort on their projects which must be noted on the budget table. Requesting salary support is optional. A letter of support from your division chief documenting that the % effort is available, and confirming investigator salary (if applicable) must be submitted with each application. If the PI is the division chief, a letter from the Department Chairperson is required.
  • Budget Justification (Download template: WORD)
    • Total costs of salary support for PI(s) and Co-I(s) must not exceed 50% of total project costs.
    • CARRA will allow up to 8% F&A (indirect) costs which must be incorporated into the project budget below. If indirect costs are requested, total costs for this project must not exceed $100,000.
    • Poster printing and publication costs are not allowed.
    • Travel expense requests are not permitted unless required for the conduct of research. Travel expenses to attend meetings to present this work, for example, are not allowed.
    • Other expenses should be discussed with CARRA personnel prior to application submission.
  • NIH-formatted Biosketches for all Principal Investigator(s), Co-Principal Investigator(s), and all Co-Investigator(s) (limit 5 pages per biosketch; please combine all biosketches into one PDF with the PI(s) biosketch listed first.)
  • Letters of Support
    • Required for budgets that include investigator effort (include letter from division chief documenting that % effort is available, and confirming investigator salary). Total costs salary support must not exceed 50% of total project costs.
    • Letters of support from collaborators, mentors and institution are highly recommended.
  • Research Assurances
    • Submit documentation of an Institutional Review Board (IRB) review. Funds will not be released until either 1) IRB approval letter or 2) IRB waiver/documentation that IRB has determined your project is exempt from IRB review is received.
  • Appendix (limit 1 attachment)

Applicants must use the templates provided when submitting their final applications. CARRA Staff is available to assist with the application process and to answer questions. Contact us by emailing [email protected].

APPLICATIONS NOT FOLLOWING THESE INSTRUCTIONS WILL NOT BE CONSIDERED.


Important Information for Large Grant Submissions

Read the CARRA-Arthritis Foundation Large Grant instructions carefully. Be sure to be compliant with formatting instructions and page limits. Use of the document templates provided above is REQUIRED. Submit your completed CARRA-Arthritis Foundation Large Grant application via the online grant submission system.

Application deadline for the CARRA-Arthritis Foundation Large Grant:

Letter of Intent: September 1
Fall Cycle: October 1

  • A maximum of 2 grants will be awarded per year.
  • The funding limit of this grant mechanism is $100,000.
  • Salary/Effort: Letters of support are required for budgets that include investigator effort (include letter from division chief documenting that % effort is available, and confirming investigator salary). Total costs salary support for the Principal Investigator(s) and Co-Investigator(s) must not exceed 50% of total project costs.
  • This is a total costs award. If indirects are requested, they must be inclusive of the maximum funding amount of $100,000. Indirects may not exceed 8%.
  • Awardees from previous grant cycles who wish to submit grant applications for the upcoming deadline must have all active Small, Large, or Fellow CARRA-Arthritis Foundation grant projects completed.
  • The project period is two years. The budget justification provided must indicate how funds are to be allocated for each year and will be paid out on an annual basis.
  • Funds will be provided to the awardee’s institution in two payments to be set up in a sundry account and used by the principal investigator according to the project budget.
    • Year 1 funding as outlined in the budget justification will be provided upfront.
    • Year 2 funding as outlined in the budget justification will distributed following submission and approval of an interim progress report at the end of year 1. Release of Year 2 funds may be contingent on IRB annual re-approval.
  • Applications proposing the collection of any new data or biosamples via the CARRA Registry and/or via CARRA sites, must include a letter of support (LOS) from CARRA's Research and Registry Oversight Committee (RROC).
  • For projects requesting budget support to cover Registry costs, requested funds will be held at CARRA and paid directly to DCRI.
  • The project period is two years beginning February 15.
  • First-time CARRA-Arthritis Foundation grant awardees are required to participate in a brief orientation.
  • A final project report is required no later than 45 days after the project period end date.
  • If the PI is unable to complete the project, any unexpended balance will be returned to CARRA.
  • Awardees are expected to submit an abstract and attend the CARRA Annual Meeting(s) until the project is complete/final.

Letter of Intent (LOI)

LOI’s are required when submitting Large Grants and are due 30 days prior to the application deadline. The LOI should be a one-page signed letter which includes:

  • A summary of the full proposal with a short description of aims of the project involved, with a clear indication of how the aims align with the intent of this application request
  • Name of the PI(s) and submitting institution
  • A list of key personnel and role(s)
  • A description of how the project aligns with CARRA's mission.

The LOI MUST be on institutional letterhead and signed by the Principal Investigator(s).

Submit Letters of Intent to [email protected].

While the LOI is an administrative requirement, it is for informational purposes only. Approval from CARRA is not needed to proceed with the full application. Investigators will receive confirmation that their LOI has been received by the CARRA grants office.

Eligibility

  • The project PI for all grants must be a current CARRA member who is up to date on membership dues and membership information (location, contact information, and membership status) is up-to-date.
  • Awardees from previous grant cycles who wish to submit grant applications for the upcoming deadline must have all active CARRA-Arthritis Foundation grant projects completed and have submitted a final progress report (template available on the CARRA website).
  • MD applicants must be at a faculty level to be eligible to submit proposals.
  • Voting Members, Emeritus Members, Research Professional Member - Investigators, Research Professional Member - Research Coordinator Members, Associate Physician Members, and Trainee Members are eligible to submit proposals.
  • All grants must be submitted by or have a pediatric rheumatologist named as a Co-Investigator.
  • Research Coordinator Member- Other, Health Care Professional Members, Fellow Members, and CARRA Executive Committee and Board of Directors members are not eligible.

Funding and Funding Period

  • Awards are total costs. Up to 8% F&A (indirect) costs are allowed, but costs must be incorporated into the project budget and not exceed the advertised award amount.
  • Publication, presentation, and travel costs should not be requested/included, unless the travel is an essential part of performing the research. Other expenses should be discussed with CARRA personnel prior to application submission.
  • Salary support will be limited to a base-salary cap of $200,000 but can include payment of local fringe rates (on top of $200,000 salary cap).
  • Please review CARRA’s statement of direct and indirect support.
  • All awards are for two years, with funding beginning February 15 of the following year.
  • Applicants will be notified of funding decisions in January.
  • If the project is not completed within the project period, the award recipient may request a no-cost extension (NCE) for up to 12 months. Requests for NCEs can be made up to 90 days prior, but no less than 30 days prior, to the project end date. An interim progress report must be submitted with the NCE Request Form, both of which are available on the CARRA website.

Reporting & Publications

  • Awardees must submit a year 1 progress report 30 days prior to the end of the first year of the project period in order to request the release of year 2 funds.
  • Awardees must submit a final progress report no later than 45 days after the project period end date.
  • Timely provision of progress reports is required for future eligibility for CARRA-Arthritis Foundation grants.
  • Awardees are expected to submit abstracts to CARRA and present their findings at the CARRA Annual Scientific Meeting(s) until the project is complete/final.
  • Awardees are expected to submit a peer-reviewed abstract to a scientific meeting based on the funded project.
  • All awardees of CARRA-Arthritis Foundation funding must abide by the procedures outlined in the CARRA Publications Policy when presenting/publishing findings from their projects. This includes submitting all abstracts and manuscripts to the CARRA Publications Committee for approval prior to submission and acknowledging the support of CARRA and the Arthritis Foundation by including the following language: “The authors wish to acknowledge CARRA, and the ongoing Arthritis Foundation financial support of CARRA.” Refer to the current Publications and Presentation Guidelines for complete details.